Salix Pharmaceuticals
Salix Pharmaceuticals is a U.S. specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders, marketing FDA-approved prescription brands including XIFAXAN, RELISTOR, TRULANCE, UCERIS, and PLENVU. A wholly-owned subsidiary of Bausch Health Companies Inc., it sells primarily through a specialty field sales force calling on gastroenterologists, hepatologists, hospitalists, and pain specialists.
- Company typePrivate
- Founded1989
- HeadquartersRaleigh, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Salix Pharmaceuticals does
Salix Pharmaceuticals is a U.S. specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal (GI) diseases and disorders. Founded in 1989 in Sunnyvale, California by Randy W. Hamilton and Lorin K. Johnson, PhD, the company relocated operations to Raleigh, North Carolina in 2000 and then to Bridgewater, New Jersey in 2014, where it currently maintains its corporate headquarters at 400 Somerset Corporate Blvd. Salix was acquired by Valeant Pharmaceuticals International in January 2015; Valeant subsequently rebranded to Bausch Health Companies Inc., and Salix now operates as a wholly-owned subsidiary of that diversified pharmaceutical parent (NYSE: BHC). The company employs 501-1,000 people and self-describes as "one of the largest specialty pharmaceutical companies in the world," with over 30 years of GI-focused experience.
Salix's product portfolio centers on FDA-approved prescription medications across multiple GI conditions. Core assets include XIFAXAN (rifaximin) 200 mg and 550 mg for overt hepatic encephalopathy and IBS-D; RELISTOR (methylnaltrexone bromide) subcutaneous injection and 150 mg tablets for opioid-induced constipation; TRULANCE (plecanatide) for chronic idiopathic constipation and IBS-C; UCERIS (budesonide) rectal foam and extended-release tablets for ulcerative colitis; and PLENVU, a 1-liter PEG bowel preparation for colonoscopies. The portfolio also includes numerous acquired/long-tail brands covering UC (APRISO, COLAZAL, GIAZO), hemorrhoids (ANUSOL-HC, PROCTOCORT), bowel prep (MOVIPREP, OSMOPREP), and adjacent metabolic/cardiometabolic conditions (GLUMETZA, FENOGLIDE, DIURIL, ZEGERID, CYCLOSET). Salix does not sell a software platform, API, or technology product.
Salix monetizes through prescription pharmaceutical sales routed via retail and hospital pharmacy channels, accessed through a dedicated specialty field sales force calling on gastroenterologists, hepatologists, hospitalists, and pain management specialists, supplemented by a primary care sales force for XIFAXAN and RELISTOR. The company layers in co-promotion agreements (e.g., LUCEMYRA with US WorldMeds; DOPTELET with Dova), HCP-facing educational platforms (GastroHub), and patient assistance/copay savings programs for RELISTOR, TRULANCE, UCERIS, and XIFAXAN. Licensing activity (Mitsubishi Tanabe S1P modulator for IBD; University of California NASH compound) and M&A (Santarus 2014; Synergy assets including Trulance 2019) have been central to pipeline and portfolio expansion.
Salix Pharmaceuticals firmographics
Firmographics- Name
- Salix Pharmaceuticals
- Legal name
- Salix Pharmaceuticals, Inc.
- Website
- https://salix.com
- Company type
- Private
- Founded year
- 1989
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Salix Pharmaceuticals is a U.S. specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders, marketing FDA-approved prescription brands including XIFAXAN, RELISTOR, TRULANCE, UCERIS, and PLENVU. A wholly-owned subsidiary of Bausch Health Companies Inc., it sells primarily through a specialty field sales force calling on gastroenterologists, hepatologists, hospitalists, and pain specialists.
- Ownership category
- akta.pro rank
Salix Pharmaceuticals industry classification
Industry- Product category
- Gastrointestinal Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gastroenterology Specialty Pharmaceuticals (HLAIACAE)
- akta.pro secondary industries
- Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Gastrointestinal & Digestive Health (HLAIADAD)
Keywords
Where Salix Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Raleigh
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Salix Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Marketing or Sales, Personnel, Technology or R&D, Operations, Supply Chain, Others
Revenue model
- Prescription Pharmaceutical Products: Salix generates revenue through the sale of prescription gastrointestinal medications including XIFAXAN, RELISTOR, TRULANCE, UCERIS, PLENVU, and other GI therapeutics through pharmacy distribution channels to healthcare providers and patients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | Patient Assistance Program for eligible patients |
| Other | Other | Copay savings programs for brand-name medications |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels7 records
Salix Pharmaceuticals product offering
Product offeringCore offering
Salix Pharmaceuticals develops, manufactures, and markets a portfolio of FDA-approved prescription medicines for the treatment of gastrointestinal and hepatic diseases in the United States. Its marketed brands address hepatic encephalopathy (XIFAXAN), opioid-induced constipation (RELISTOR), irritable bowel syndrome with constipation (TRULANCE), ulcerative colitis (UCERIS), and bowel preparation prior to colonoscopy (PLENVU). The company sells primarily to healthcare providers and institutional buyers through wholesale distribution and a specialty sales force.
Product overview
Salix Pharmaceuticals is a specialty pharmaceutical company and wholly-owned subsidiary of Bausch Health Companies Inc., focused on the prevention and treatment of gastrointestinal (GI) diseases and disorders. The company operates as a pharmaceutical product portfolio rather than a technology platform, offering a broad range of prescription medications. The core GI-focused products include XIFAXAN (rifaximin) for overt hepatic encephalopathy and IBS-D, RELISTOR (methylnaltrexone bromide) in both subcutaneous injection and oral tablet formulations for opioid-induced constipation, TRULANCE (plecanatide) for chronic idiopathic constipation and IBS-C, UCERIS (budesonide) in rectal foam and extended-release tablet formulations for ulcerative colitis, and PLENVU for bowel preparation before colonoscopies. The portfolio also includes numerous acquired and licensed brands treating related GI conditions such as ulcerative colitis (APRISO, COLAZAL, GIAZO), hemorrhoids (ANUSOL-HC, PROCTOCORT), as well as metabolic and cardiovascular products (GLUMETZA, FENOGLIDE, DIURIL, ZEGERID). The company does not offer a technology platform, API, or software products.
Differentiator
Problem solved
Functional benefit
Products and services
- XIFAXAN (rifaximin) FDA-approved oral prescription antibiotic (rifaximin) indicated to reduce the risk of overt hepatic encephalopathy recurrence in adults and to treat travelers' diarrhea caused by noninvasive strains of E. coli; prescribed primarily by hepatologists and gastroenterologists.
- RELISTOR (methylnaltrexone bromide) FDA-approved prescription therapy for opioid-induced constipation in adults with chronic non-cancer pain and in adults with advanced illness; available in subcutaneous and oral formulations.
- TRULANCE (plecanatide) FDA-approved oral prescription therapy indicated for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation (IBS-C).
- UCERIS (budesonide) FDA-approved prescription formulation of budesonide for the induction of remission in patients with active, mild to moderate ulcerative colitis.
- PLENVU FDA-approved low-volume prescription bowel preparation (polyethylene glycol-based) used to cleanse the colon in adults prior to colonoscopy.
Quantifiable outcome
- Xifaxan (rifaximin) treatment following OHE hospitalization associated with reduced risk of 30-day OHE rehospitalization
- +1 more outcomes
Companies that use Salix Pharmaceuticals
Customer profileNamed customers2 records
Segments6 records
Ideal customer profiles1 record
Salix Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Salix Pharmaceuticals partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- PulsePointcoreSalix served as an early development partner for PulsePoint's Ad Server Creative ID Reporting capability, which connects ad server creative data to individual physician-level (NPI) insights. Salix piloted the capability to enable true omnichannel personalization and segment messaging at the provider level for healthcare marketers.
- Ardelyx Inc.minorArdelyx Inc. serves as the lead partner for World IBS Day 2026, joined by Salix Pharmaceuticals as a global supporter alongside ModifyHealth, Tuutapp.net, and Monash University.
- ModifyHealthminorModifyHealth joined Salix Pharmaceuticals as a global supporter for World IBS Day 2026.
- Monash UniversityminorMonash University joined Salix Pharmaceuticals as a global supporter for World IBS Day 2026.
- The U.S. Pain FoundationminorSalix collaborated with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders to establish the inaugural Opioid-Induced Constipation (OIC) Awareness Day.
- International Foundation for Gastrointestinal DisordersminorSalix collaborated with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders to establish the inaugural OIC Awareness Day.
- Bellamy YoungminorSalix Pharmaceuticals partnered with Bellamy Young (actress and singer) for awareness and advocacy initiatives.
- Colon Cancer CoalitionminorSalix and Colon Cancer Coalition joined forces for the 'Faces of Blue' story series to raise awareness of colorectal cancer screenings.
- Mitsubishi Tanabe PharmacoreSalix entered into an exclusive license agreement with Mitsubishi Tanabe Pharma to develop and commercialize a late-stage investigational S1P modulator for the treatment of inflammatory bowel disease.
- University of CaliforniacoreSalix entered into a license agreement with the University of California to develop and commercialize a novel compound for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
- Dova PharmaceuticalsminorDova Pharmaceuticals and Salix entered into an exclusive co-promotion agreement for DOPTELET (avatrombopag).
- Cedars-Sinai Medical CentercoreSalix expanded microbiome research and discovery through strategic collaboration with Cedars-Sinai Medical Center.
- US WorldMedsminorSalix and US WorldMeds entered into an exclusive co-promotion agreement for opioid withdrawal treatment LUCEMYRA (lofexidine).
Scale indicators4 records
Recent moves8 records
Expansion highlights6 records
Salix Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Pfizer: Large pharma with competing ulcerative colitis/IBD therapies (Xeljanz) and broader gastroenterology presence — broader portfolio but meaningful overlap with Salix's UCERIS/APRISO business.
- Merck & Co. Diversified pharma with relevant gastroenterology research programs and competitive presence in the broader specialty pharma landscape where Salix operates; a broad incumbent with overlapping HCP engagement.
- AbbVie: Through its Allergan acquisition, AbbVie holds LINZESS rights and competes with Salix's UC franchise via SKYRIZI and RINVOQ — a broad incumbent with overlapping GI and IBD biologics that compete for the same gastroenterology budget.
- Sanofi: Global pharma with gastroenterology and inflammatory bowel disease programs (Dupixent in EoE/IBD-adjacent) overlapping the HCP gastroenterology channel Salix serves — a broader incumbent with intersecting GI strategy.
- Eli Lilly: Large pharma with emerging gastroenterology assets and competing immunology programs relevant to Salix's UC and IBD-adjacent portfolio; comparable as a broad incumbent competitor in the HCP specialty channel.
- Takeda Pharmaceutical: Global pharma with a major GI franchise (Entyvio for IBD, Shire legacy products) competing against Salix in ulcerative colitis and broader gastroenterology; broader portfolio but materially overlapping indications.
Direct peers
- Ardelyx: Specialty GI company that developed tenapanor (IBSRELA/XPHOZAH), addressing IBS-C and hyperphosphatemia; directly comparable as a smaller GI-pure-play rival also targeting the same prescriber base.
- Ferring Pharmaceuticals: Privately-held specialty pharma with a deep GI franchise (e.g., REBYOTA for C. difficile, gastroenterology focus); comparable as a peer specialty company pursuing similar gastroenterology HCP channels.
- Sebela Pharmaceuticals: US-focused specialty pharma with GI products (e.g., Teglutik, Pizensy/lactulose franchise); closely comparable as a US-centric, GI-focused specialty company with a similar enterprise sales model.
- Ironwood Pharmaceuticals: GI-focused specialty pharma that co-markets LINZESS (linaclotide) for IBS-C and chronic idiopathic constipation — Salix's TRULANCE competes head-to-head in this category, making the two direct US competitors.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Salix Pharmaceuticals social profiles
Digital presenceSalix Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Salix Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles7 records
Salix Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Salix Pharmaceuticals M&A and investment
M&A and investmentM&A2 records
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Salix Pharmaceuticals
What does Salix Pharmaceuticals do?
Salix Pharmaceuticals develops, manufactures, and markets a portfolio of FDA-approved prescription medicines for the treatment of gastrointestinal and hepatic diseases in the United States. Its marketed brands address hepatic encephalopathy (XIFAXAN), opioid-induced constipation (RELISTOR), irritable bowel syndrome with constipation (TRULANCE), ulcerative colitis (UCERIS), and bowel preparation prior to colonoscopy (PLENVU). The company sells primarily to healthcare providers and institutional buyers through wholesale distribution and a specialty sales force.
Is Salix Pharmaceuticals a public or private company?
Salix Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.
When was Salix Pharmaceuticals founded?
Salix Pharmaceuticals was founded in 1989. It employs 501 to 1,000 people.
Where is Salix Pharmaceuticals based?
Salix Pharmaceuticals is headquartered in Raleigh, United States, in the North America region.
How does Salix Pharmaceuticals make money?
One revenue line is on record: prescription Pharmaceutical Products.
Who are Salix Pharmaceuticals's main competitors?
Broad incumbents on record are Pfizer, Merck & Co., AbbVie, Sanofi, Eli Lilly and Takeda Pharmaceutical. Direct peers are Ardelyx, Ferring Pharmaceuticals, Sebela Pharmaceuticals and Ironwood Pharmaceuticals.
Does Salix Pharmaceuticals have an API?
No public API is recorded for Salix Pharmaceuticals.
What industry is Salix Pharmaceuticals in?
Salix Pharmaceuticals's product category is Gastrointestinal Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals, with a secondary code of HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.